These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. Xu T; Chen J; Lu Y; Wolff JE BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214 [TBL] [Abstract][Full Text] [Related]
10. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689 [TBL] [Abstract][Full Text] [Related]
12. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U Oncology; 2013; 85(3):191-5. PubMed ID: 24008924 [TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
14. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital. Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575 [TBL] [Abstract][Full Text] [Related]
15. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583 [TBL] [Abstract][Full Text] [Related]
16. Using bevacizumab in the fight against malignant glioma: first results in Asian patients. Pu JK; Chan RT; Ng GK; Leung GK; Hung KN; Fung CF Hong Kong Med J; 2011 Aug; 17(4):274-9. PubMed ID: 21813894 [TBL] [Abstract][Full Text] [Related]
17. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064 [TBL] [Abstract][Full Text] [Related]
18. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; Sathornsumetee S; McLendon RE; Herndon JE; Marcello JE; Norfleet J; Friedman AH; Bigner DD; Friedman HS Br J Cancer; 2009 Dec; 101(12):1986-94. PubMed ID: 19920819 [TBL] [Abstract][Full Text] [Related]
19. [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma]. Tabatabai G; Stupp R Nervenarzt; 2010 Aug; 81(8):936-9. PubMed ID: 20669004 [TBL] [Abstract][Full Text] [Related]
20. Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Wiestler B; Radbruch A; Osswald M; Combs SE; Jungk C; Winkler F; Bendszus M; Unterberg A; Platten M; Wick W; Wick A J Neurooncol; 2014 Mar; 117(1):85-92. PubMed ID: 24458956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]